Cancer incidence and mortality in Serbia 1999–2009 by Jovan Mihajlović et al.
Mihajlović et al. BMC Cancer 2013, 13:18
http://www.biomedcentral.com/1471-2407/13/18RESEARCH ARTICLE Open AccessCancer incidence and mortality in Serbia
1999–2009
Jovan Mihajlović1*, Petros Pechlivanoglou1, Marica Miladinov-Mikov2,3, Snežana Živković4 and Maarten J Postma1Abstract
Background: Despite the increase in cancer incidence in the last years in Serbia, no nation-wide, population-based
cancer epidemiology data have been reported. In this study cancer incidence and mortality rates for Serbia are
presented using nation-wide data from two population-based cancer registries. These rates are additionally
compared to European and global cancer epidemiology estimates. Finally, predictions on Serbian cancer incidence
and mortality rates are provided.
Methods: Cancer incidence and mortality was collected from the cancer registries of Central Serbia and Vojvodina
from 1999 to 2009. Using age-specific regression models, we estimated time trends and predictions for cancer
incidence and mortality for the following five years (2010–2014). The comparison of Serbian with European and
global cancer incidence/mortality rates, adjusted to the world population (ASR-W) was performed using Serbian
population-based data and estimates from GLOBOCAN 2008.
Results: Increasing trends in both overall cancer incidence and mortality rates were identified for Serbia. In men,
lung cancer showed the highest incidence (ASR-W 2009: 70.8/100,000), followed by colorectal (ASR-W 2009:
39.9/100,000), prostate (ASR-W 2009: 29.1/100,000) and bladder cancer (ASR-W 2009: 16.2/100,000). Breast cancer
was the most common form of cancer in women (ASR-W 2009: 70.8/100,000) followed by cervical (ASR-W 2009:
25.5/100,000), colorectal (ASR-W 2009: 21.1/100,000) and lung cancer (ASR-W 2009: 19.4/100,000). Prostate and
colorectal cancers have been significantly increasing over the last years in men, while this was also observed for
breast cancer incidence and lung cancer mortality in women. In 2008 Serbia had the highest mortality rate from
breast cancer (ASR-W 2008: 22.7/100,000), among all European countries while incidence and mortality of cervical,
lung and colorectal cancer were well above European estimates.
Conclusion: Cancer incidence and mortality in Serbia has been generally increasing over the past years. For a
number of cancer sites, incidence and mortality is alarmingly higher than in the majority of European regions. For
this increasing trend to be controlled, the management of risk factors that are present among the Serbian
population is necessary. Additionally, prevention and early diagnosis are areas where significant improvements
could still be made.
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Cancer is the leading cause of mortality in the developed
world and the second leading cause in the developing
world [1]. However, systematic data collection in cancer
epidemiology over the last 30 years has facilitated the as-
sessment and control of the disease on a global level [2-4].
More recently, cancer reporting and monitoring projects,
such as the GLOBOCAN 2008, have provided both region-
and country-specific estimates of the burden of cancer [5].
Where country-specific data were not readily available,
these projects would frequently estimate national incidence
and mortality rates using incomplete or indirect evidence.
Given the lack of complete data for Serbia, the estimates of
incidence have been so far based on local cancer registries
and extrapolated to the nation’s population [5].
The first cancer registries in Serbia were formed in
1970, but became obligatory practice after a change of
legal acts in 1986 [6]. Since their formation, information
was collected separately by the two cancer registries of
Serbia: the Cancer Registry of Central Serbia (CRCS) [6]
and the Cancer Registry of Vojvodina (CRV) [unpub-
lished data – Miladinov-Mikov]. In the period from
1986 to 1998, quality of data collection from these two
registries was rather poor, but, in 1998 they both became
members of the International Agency for Research on
Cancer and a new methodology has been applied which
substantially improved data quality [6]. Although to-
gether these two registries monitor the whole Serbian
population (excluding Kosovo and Metohija), they have
never published cancer estimates on a national level.
Consequently, epidemiological studies presented in the
literature either relied on one of the registries, were fo-
cused on specific cancer sites, referred to estimates from
earlier periods or only reported data for smaller time
intervals [7-9].
The aim of this work is to present nation-wide Serbian
cancer incidence and mortality rates using population-
based data and to analyse them with respect to the glo-
bal and European cancer incidence and mortality rates.
Additionally, future predictions until the year 2014 on
Serbian cancer incidence and mortality rates are also
provided. According to the authors’ knowledge, this is
the first time that such nation-wide population-based
cancer data are presented for Serbia. This study is
expected to enable the evaluation of cancer burden on
the society and help decision makers in planning onco-
logical preventive and curative health care.
Methods
Data sources
Local incidence and mortality data were extracted from
the CRV and the CRCS, for the period between 1999
and 2009 [unpublished data - Miladinov-Mikov, 6].
Information on incidence and mortality were providedby the registries in age-stratified format in five-year age
groups. Validity of the collected data was assessed
through the percentage of microscopically (histologi-
cally) verified cancers (MV%) and the percentage of
cancers certified only after death (DCO%) [10]; complete-
ness was assessed through the mortality/incidence ratio
(M/I) [11] (Table 1). Malignant tumours were coded
according to the Tenth Revision of International Classifica-
tion of Diseases (codes C00-C96) [12]. Demographical data
were collected from the census in 2002 and estimates of
the Statistical Office of the Republic of Serbia, for all other
years of the study period [13].
In order to standardise the incidence and mortality
rates to the world population (age-standardised rates on
world population - ASR-W), the following procedure
was applied for the ten most common cancer sites in
each year. Firstly, we aggregated all new cases/deaths
from the two registries per age group. Secondly, we
divided these with the age-stratified population estimates
for every year, thus calculating the age-specific incidence
and mortality rates. Finally, direct standardisation with
the world population was performed as defined by Segi
et al. [14] and incidence and mortality ASR-Ws were
obtained for the whole of Serbia.
Predictions and trends
Next to descriptive information on cancer epidemiology,
we aimed to provide predictions of cancer incidence and
mortality. Since the quality of registration of new cases
has been gradually improving through time, as also
shown in Table 1, incidence rates reported in the earlier
years (1999–2000) might be less useful for explaining
the present and predicting future rates. For this reason,
we utilized a prediction method which selectively chooses
the most informative sample period, in order to predict in-
cidence/mortality ASR-Ws for the years between 2010
and 2014 [15]. In particular, we used two different regres-
sion models: (i) one assuming a linear, age-specific change
of incidence/mortality rate over time and (ii) one assum-
ing a linear, age-specific relation between time and the
logarithm of incidence/mortality ASR-Ws [15]. These
models were used to predict the incidence/mortality rate
for a target year, decided to be the latest year of the study
period (2009). The former model focuses on the absolute
change of incidence or mortality rate while the latter fo-
cuses on the proportional change of the rate. Hence, inter-
pretation of the regression parameters should be done
cautiously for each model.
In order to identify the most informative sample
period for this prediction, we applied both models using
information on incidence/mortality from the last four
years before 2009 (i.e.2005:2008) and gradually added
previous years one by one, up until 2001. This procedure
resulted in 2×5 prediction models for age-specific
Table 1 Data quality indicators for cancer registry of






Year of report DCO% MV% M/I DCO% MV% M/I
1999 15.4 68.3 62.7 8.0 52.5 66.5
2000 12.3 69.8 57.2 N/A N/A 69.4
2001 2.3 N/A 54.4 N/A N/A 60.1
2002 3.1 92.6 54.7 N/A N/A 61.8
2003 5.7 91.4 56.3 N/A N/A 62.9
2004 5.5 88.4 55.4 N/A N/A 60.0
2005 5.5 87.2 57.5 N/A N/A 59.1
2006 2.9 86.8 57.4 N/A N/A 58.5
2007 5.3 84.0 56.0 N/A N/A 61.0
2008 5.4 87.1 58.1 4.5 84.6 57.0
2009 N/A N/A 56.4 N/A N/A 57.5
Legend: DCO% - percentage of cancers certified only after death, MV% –
percentage of microscopically verified cancers, M/I mortality/incidence ratio,
N/A – data not available.
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appropriate model was then based on the calculated
standardized incidence and mortality ratios of the
recorded versus the predicted number of total cancer
cases or deaths for the target year (2009). The implicit
assumption in this method is that the model that makes
the best prediction for the most recent available year will
also make the best prediction for the future years. After
the best fitting model was chosen, predictions for the
years 2010–2014 were made. The same model was also
used for the estimation of the trend of increase or de-
crease in the incidence/mortality ASR-Ws through time.
All computation within the analysis was conducted using
the statistical software R (v.2.13.2) [16].Comparison with the GLOBOCAN 2008 data
Contrasting the incidence and mortality of cancer in
Serbia with that in other countries and regions in
Europe, as well as worldwide, can establish the relative
burden of cancer in Serbia. For that reason we com-
pared the incidence and mortality ASR-Ws from the
GLOBOCAN 2008 project [5] with the corresponding
rates from Serbia in 2008. Site-specific cancer inci-
dence and mortality ASR-Ws were extracted from the
Serbian cancer registries and from GLOBOCAN 2008
for the European countries with the highest and lowest
incidence/mortality, all European regions (Southern,
Central-eastern, Western and Northern), and the world
in total. It should be noted that according to the re-
gional division in GLOBOCAN 2008, Serbia belonged
to the countries of Southern Europe [17].Results
Table 2 presents the number of new cases and the inci-
dence rates for the ten most common cancer sites as
well as for all cancer sites combined from 1999 to 2009.
In 1999 there were 26,121 incident cancer cases in
Serbia (ASR-W: 209.9/100,000, ASR-W in men: 228.9/
100,000, ASR-W in women: 197.5/100,000), while this
increased to 36,308 newly diagnosed with cancer in 2009
(ASR-W: 277.2/100,000, ASR-W in men: 307.2/100,000,
ASR-W in women: 256.4/100,000). For men, lung cancer
had the highest incidence rate varying from ASR-W
55.5/100,000 in 1999 to ASR-W 70.8/100,000 in 2009.
This was followed by the incidence of colorectal (ASR-W
1999–2009: 27.5/100,000-39.9/100,000), prostate (ASR-W
1999–2009: 12.2/100,000-29.5/100,000) and bladder cancer
(ASR-W 1999–2009: 11.7/100,000-16.2/100,000). Among
women the most frequently observed cancer in 2009 was
breast (ASR-W 1999–2009: 51.5/100,000-70.8/100,000), fol-
lowed by cervical (ASR-W 1999–2009: 22.7/100,000-25.5/
100,000), colorectal (ASR-W 1999–2009: 16.4/100,000-
21.1/100,000) and lung cancer (ASR-W 1999–2009: 12.0/
100,000-19.4/100,000).
Table 3 presents the mortality rates and the number of
fatal cases, from 1999 to 2009, for the ten most common
cancer sites and for all sites combined. In Serbia 1999,
17,375 people died from cancer (ASR-W: 129.6/100,000,
ASR-W in men: 163.2/100,000, ASR-W in women:
102.7/100,000) while the number inclined to 21,069 can-
cer deaths in 2009 (ASR-W: 143.8/100,000, ASR-W in
men: 181.1/100,000, ASR-W in women: 113.8/100,000).
The highest mortality rate for men was observed for
lung cancer (ASR-W 1999–2009: 48.5/100,000-58.0/
100,000) followed by colorectal (ASR-W 1999–2009:
17.8/100,000-21.9/100,000), stomach (ASR-W 1999–2009:
12/100,000-10.8/100,000) and prostate cancer (ASR-W
1999–2009: 9.1/100,000-11.5/100,000). In women, the
highest mortality rates were attributed to breast (ASR-W
1999–2009: 22.3/100,000-22.5/100,000), lung (ASR-W
1999–2009: 10.0–16.7/100,000), colorectal (ASR-W
1999–2009: 10.4/100,000-12.0/100,000) and cervical
cancer (ASR-W 1999–2009: 7.4/100,000-7.2/100,000).
Predictions and trends
Figure 1 presents the overall ASR-W cancer incidence
and mortality for men and women from 1999 to 2009
(solid lines). In addition, predictions until 2014 for over-
all cancer incidence and mortality are presented (dotted
lines). An increasing time trend can be observed for can-
cer incidence and mortality in both genders. In particu-
lar, linear regressions of time on the log of mortality and
incidence revealed that, in men, incidence and mortality
ASR-Ws increased by 2.5% (P = 0.004) and 1% (P < 0.001)
per year, respectively. For women, the incidence ASR-W
was estimated to be increasing by 2.22% per year, although
Table 2 Cancer incidence and number of new cancer cases in Serbia from 1999 to 2009
Number of new cancer cases and incidence ASR-Ws/100,000, male population
Year of report
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Lung and bronchus (C34) Cases 3,281 3,621 4,135 4,131 4,092 4,139 3,992 4,044 3,795 4,193 4,354
ASR-W 55.5 60.7 69.0 67.6 67.2 67.9 65.4 66.7 61.3 68.0 70.8
Colon and rectum (C18-C20) Cases 1,690 1,729 1,953 2,130 2,166 2,202 2,240 2,094 2,459 2,698 2,566
ASR-W 27.5 28.1 31.6 33.5 34.2 34.6 35.1 32.8 38.7 41.5 39.9
Prostate (C61) Cases 813 973 1,127 1,279 1,333 1,354 1,501 1,662 1,776 1,891 2,193
ASR-W 12.2 14.4 16.3 17.4 18.9 19.1 20.9 22.9 23.9 25.9 29.5
Bladder (C67) Cases 733 890 955 1,044 951 1,000 1,009 1,045 1,126 1,044 1,071
ASR-W 11.7 14.4 14.9 16.0 14.8 15.5 15.8 15.7 16.8 15.6 16.2
Stomach (C16) Cases 801 837 908 972 857 840 789 747 890 855 729
ASR-W 13.3 13.6 14.8 15.4 13.6 13.1 12.4 11.9 13.9 13.2 11.1
Larynx (C32) Cases 604 677 721 709 679 665 618 732 677 661 626
ASR-W 10.5 11.7 12.4 12.1 11.6 11.2 10.6 12.5 11.4 11.2 10.6
Brain (C71) Cases 349 378 377 414 465 473 396 423 413 393 396
ASR-W 7.1 8.0 7.9 8.5 9.3 9.9 7.7 8.6 8.0 7.9 7.9
Mouth and pharynx (C00-C10) Cases 430 532 494 474 468 457 454 473 435 516 493
ASR-W 7.5 9.3 8.6 8.1 8.0 7.7 7.7 7.9 7.3 8.6 8.2
Leukemias (C91-C95) Cases 302 304 332 339 386 335 348 308 405 309 318
ASR-W 6.5 6.9 7.0 6.9 8.0 6.7 6.8 6.2 7.4 5.8 6.6
Pancreas (C25) Cases 326 337 432 435 399 458 434 383 457 476 450
ASR-W 5.4 5.6 7.0 7.0 6.3 7.5 7.0 6.1 7.4 7.3 7.1
All sites (C00-C97) Cases 13,344 15,062 16,128 16,670 16,617 17,049 16,943 17,349 17,801 18,565 19,076
ASR-W 228.9 255.8 272.8 274.3 276.0 283.2 277.5 284.0 286.3 296.1 307.2
Number of new cancer cases and incidence ASR-Ws/100,000, female population
Year of report
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Breast (C50) Cases 3,193 3,692 3,807 3,935 3,866 3,625 3,650 3,791 3,865 4,026 4,518
ASR-W 51.5 59.3 60.4 63.0 60.2 56.9 57.1 58.9 59.9 62.0 70.8
Cervix uteri (C53) Cases 1,271 1,341 1,376 1,380 1,287 1,236 1,276 1,392 1,183 1,276 1,423
ASR-W 22.7 24.1 25.6 25.1 23.2 22.7 23.3 24.9 21.1 23.0 25.5
Colon and rectum (C18-C20) Cases 1,203 1,241 1,382 1,492 1,549 1,575 1,591 1,595 1,768 1,642 1,614
ASR-W 16.4 16.8 18.7 19.6 20.3 20.9 20.8 20.9 23.1 21.1 21.1
Lung and bronchus (C34) Cases 808 1,026 1,114 1,172 1,178 1,288 1,178 1,173 1,152 1,358 1,383
ASR-W 12.0 15.3 16.4 16.9 16.7 18.3 17.0 16.8 16.1 19.5 19.4
Corpus uteri (C54) Cases 763 829 767 772 829 827 869 823 844 895 954
ASR-W 11.7 12.4 11.9 11.7 12.0 12.5 12.5 12.2 12.5 13.1 14.1
Ovary (C56) Cases 595 641 623 641 606 638 694 602 616 652 626
ASR-W 9.8 10.5 10.0 10.6 9.8 10.4 11.5 9.8 9.8 10.9 10.3
Stomach (C16) Cases 404 468 463 502 512 561 493 492 507 482 413
ASR-W 5.3 6.3 6.2 6.5 6.3 7.1 6.6 6.3 6.5 6.1 5.2
Brain (C71) Cases 232 288 301 317 315 370 308 310 329 310 330
ASR-W 4.5 5.9 6.0 6.0 6.1 6.9 5.3 5.8 5.9 5.4 6.2
Leukaemias (C91-C95) Cases 215 213 259 270 263 252 253 225 294 186 205
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Table 2 Cancer incidence and number of new cancer cases in Serbia from 1999 to 2009 (Continued)
ASR-W 4.1 3.9 4.7 5.1 5.1 4.6 4.6 4.0 4.9 3.2 3.7
Pancreas (C25) Cases 265 270 289 331 337 349 412 286 347 328 357
ASR-W 3.5 3.5 3.7 4.3 4.2 4.3 5.0 3.7 4.1 3.9 4.4
All sites (C00-C97) Cases 12,777 14,655 14,943 15,427 15,484 15,786 15,684 15,817 15,923 16,666 17,232
ASR-W 197.5 225.9 230.6 235.7 233.6 236.9 233.8 235.1 232.3 244.3 256.4
Legend: ASR-W – age-standardised rate on world population. Codes in brackets next to presented cancer sites are in accordance with the Tenth Revision of
International Classification of Diseases (codes C00-C96).
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cancer mortality rate for women was found to be signifi-
cantly increasing by 1% (p < 0.001) per year.
Figure 2 presents the time trend for cancer incidence
and mortality rates for the four main cancer sites in men
and women from 1999 to 2009 as well as incidence and
mortality rates’ predictions from 2010 to 2014. Linear
regressions of time on incidence revealed that in both
genders all cancer sites analysed showed a positive trend
over time. In men, the incidence of prostate cancer has
been increasing with 1.948/100,000 (P < 0.001) per year,Table 3 Cancer mortality and number of cancer deaths in Ser
Number of cancer
Cancer site 1999 2000 2001 200
Lung and bronchus (C34) Deaths 2,915 3,054 3,107 3,19
ASR-W 48.5 50.4 50.8 51.
Colon and rectum (C18-C20) Deaths 1,124 1,158 1,167 1,24
ASR-W 17.8 18.3 18.1 18.
Stomach (C16) Deaths 742 769 767 788
ASR-W 12.0 12.3 12.2 12.
Prostate (C61) Deaths 610 535 605 680
ASR-W 9.1 7.9 8.6 8.9
Pancreas (C25) Deaths 403 391 417 435
ASR-W 6.6 6.3 6.6 6.7
Liver (C22) Deaths 383 419 389 352
ASR-W 6.1 6.6 6.1 5.4
Larynx (C32) Deaths 403 409 384 357
ASR-W 6.7 6.9 6.4 5.9
Brain (C71) Deaths 292 295 289 271
ASR-W 5.8 5.8 5.5 5.0
Bladder (C67) Deaths 371 344 386 453
ASR-W 5.7 5.3 5.8 6.5
Leukaemias (C91-C95) Deaths 238 228 252 230
ASR-W 4.3 4.1 4.5 4.0
All sites (C00-C97) Deaths 9,870 10,179 10,175 10,6
ASR-W 163.2 166.3 164.7 166faster than any other cancer analysed in the male popu-
lation. A significant increase was also observed for the
incidence ASR-W of colorectal cancer with approxi-
mately 1.084/100,000 (P = 0.013). In women, breast can-
cer showed the highest increase in incidence with an
additional ASR-W of 3.065/100,000 (P = 0.034) every
year. In the analysis of mortality ASR-Ws, colorectal
cancer in men and lung cancer in women were esti-
mated to have the most significant increase over time:
0.42/100,000 (P = 0.036) and 0.626/100,000 (P < 0.001)
per year, respectively.bia from 1999 to 2009
deaths and mortality ASR-Ws/100,000, male population
Year of report
2 2003 2004 2005 2006 2007 2008 2009
9 3,212 3,350 3,454 3,647 3,678 3,717 3,676
6 51.9 54.1 55.4 58.2 58.0 59.1 58.0
4 1,205 1,309 1,383 1,338 1,367 1,438 1,537
8 18.3 19.7 20.8 19.9 19.6 20.8 21.9
753 787 730 657 713 691 735
0 11.6 11.9 11.1 10.1 10.7 10.4 10.8
760 759 819 881 948 927 977
10.3 10.1 10.5 11.1 11.8 11.5 11.5
442 459 502 488 491 534 520
6.9 7.2 7.9 7.6 7.4 7.9 7.9
390 374 373 412 468 420 438
6.0 5.6 5.7 6.1 6.9 6.3 6.4
426 366 358 382 366 356 391
6.9 5.9 5.6 6.2 5.8 5.6 6.2
327 306 321 338 379 322 331
6.0 5.4 6.0 6.4 6.6 5.9 5.7
417 426 403 495 472 407 453
6.0 6.1 5.6 7.0 6.4 5.5 6.0
249 231 279 281 342 293 299
4.4 4.0 4.9 4.6 5.7 4.6 4.9
35 10,690 10,982 11,169 11,495 11,736 11,775 11,999
.6 169.3 172.0 174.2 177.3 179.0 179.6 181.1
Table 3 Cancer mortality and number of cancer deaths in Serbia from 1999 to 2009 (Continued)
Number of cancer deaths and mortality ASR-Ws/100,000, female population
Year of report
Cancer site 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009
Breast (C50) Deaths 1,497 1,511 1,515 1,464 1,608 1,628 1,676 1,643 1,623 1,653 1,674
ASR-W 22.3 22.6 21.9 20.8 23.0 23.3 23.3 22.2 21.2 22.7 22.5
Lung and bronchus (C34) Deaths 712 790 810 857 911 957 980 1,089 1,096 1,107 1,265
ASR-W 10.0 11.1 11.2 11.8 12.4 13.0 13.1 14.9 14.5 14.9 16.7
Colon and rectum (C18-C20) Deaths 813 845 841 905 937 957 1,070 1,036 990 1,065 1,073
ASR-W 10.4 10.4 10.3 10.5 11.3 11.5 12.5 12.1 11.0 12.3 12.0
Cervix uteri (C53) Deaths 486 471 490 543 501 497 519 523 523 536 490
ASR-W 7.4 7.4 7.7 8.3 7.4 7.6 7.9 8.0 7.7 8.2 7.2
Stomach (C16) Deaths 400 436 407 397 424 468 452 393 412 393 417
ASR-W 5.0 5.6 5.2 4.8 4.9 5.7 5.5 4.7 4.9 4.6 5.3
Ovary (C56) Deaths 335 311 363 331 341 348 374 402 390 388 424
ASR-W 4.9 4.7 5.2 4.8 4.9 5.0 5.1 5.8 5.4 5.5 5.9
Pancreas (C25) Deaths 306 318 323 349 372 349 448 366 475 435 447
ASR-W 3.9 3.9 3.9 4.2 4.5 4.0 5.1 4.3 5.2 4.8 4.8
Brain (C71) Deaths 192 206 214 232 227 231 233 281 279 255 292
ASR-W 3.2 3.3 3.6 3.9 3.6 3.9 3.6 4.2 4.3 4.0 4.4
Liver (C22) Deaths 256 293 275 242 251 278 266 304 312 260 291
ASR-W 3.1 3.7 3.3 2.9 3.1 3.1 3.1 3.4 3.6 2.9 3.3
Leukaemias (C91-C95) Deaths 195 175 196 186 187 176 175 233 223 215 224
ASR-W 3.1 2.6 3.0 2.8 2.7 2.5 2.6 3.5 2.9 2.9 2.9
All sites (C00-C97) Deaths 7,505 7,694 7,742 7,911 8,169 8,380 8,572 8,722 8,681 8,787 9,070
ASR-W 102.7 104.0 103.6 103.7 106.2 108.0 108.8 110.4 108.6 112.7 113.8
Legend: ASR-W – age-standardised rate on world population. Codes in brackets next to presented cancer sites are in accordance with the Tenth Revision of
International Classification of Diseases (codes C00-C96).
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Figure 3A presents the men’s incidence ASR-Ws in Serbia
for 2008 against European and worldwide estimates that
were extracted from GLOBOCAN 2008. The incidence of
lung (ASR-W: 68.0/100,000) and colorectal (ASR-W:41.5/
100,000) cancer in Serbia was higher than the average inci-
dence in any European region or in the world. Conversely,
prostate cancer in Serbia had a lower incidence rate
(ASR-W: 25.9/100,000) than the average in all European
regions or the world (ASR-W: 27.9/100,000 – 93.1/
100,000). Finally, the overall cancer incidence in the Serbian
male population (ASR-W: 296.1/100,000) was closest to the
average incidence in Southern Europe (ASR-W: 289.1/
100,000). The mortality rates for lung (ASR-W: 59.1/
100,000) and colorectal cancer (ASR-W: 20.8/100,000) for
men in Serbia were also above the average European and
world mortality rates (Figure 3B). Similarly, the overall mor-
tality rate (ASR-W: 179.6/100,000) was higher than world
and European averages and comparable to Hungary, the
country with the highest cancer mortality in Europe
(ASR-W: 229.5/100,000). On the contrary, the mortalityrate for prostate cancer (ASR-W: 11.5/100,000) in Serbia
was similar to the European average.
The women’s cancer incidence in Serbia, Europe and
the world, for 2008, are presented in Figure 4A. The in-
cidence of cervical cancer in Serbia (ASR-W: 23.0/
100,000) was observed to be higher than all average
European/global estimates and almost equal to the high-
est European rate found in Romania (ASR-W: 23.9/
100,000). The incidence of breast (ASR-W: 62.0/
100,000), colorectal (ASR-W: 21.1/100,000) lung (ASR-W:
19.5/100,000) and all cancers combined (ASR-W: 244.3/
100,000) in Serbia was close to the average value of the
comparators. Finally, comparison of women’s cancer
mortality indicated that breast cancer mortality in
Serbia (ASR-W: 22.7/100,000) was the highest in Europe in
2008 (Figure 4B). Additionally, mortality of colorectal
(ASR-W: 12.3/100,000) cervical cancer (ASR-W: 8.2/
100,000) and overall cancer (ASR-W: 112.7/100,000) in
Serbian women was above the average regional and global
estimates though below the countries with the highest
European rates.
Figure 2 Trends in incidence and mortality from the four most common cancers in Serbia (1999–2009) and predictions (2010–2014).
Legend: Blue line – lung cancer. Orange line – colorectal cancer. Turquoise line – prostate cancer. Green line – bladder cancer. Dark red
line – stomach cancer. Pink line – breast cancer. Light green line – cervical cancer.
Figure 1 Overall cancer incidence and mortality in Serbia - trends (1999–2009) and predictions (2010–2014). Legend: Red bold line –
incidence, men. Red regular line – incidence, women. Black bold line – mortality, men. Black regular line, mortality, women. All dotted lines
continuous to these are depicting predictions.
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Figure 3 (A) Comparison of Serbian incidence ASR-Ws with the GLOBOCAN 2008 estimates – men; (B), Comparison of Serbian
mortality ASR-Ws with the GLOBOCAN 2008 estimates – men. N Europe – Northern Europe, S Europe – Southern Europe, W Europe –
Western Europe, CE Europe – Central Eastern Europe. * - Eureopan country with the lowest incidence/mortality ASR-W. ** - European country
with the highest incidence/mortality ASR-W.
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This study presents, for the first time, nation-wide data
on incidence and mortality from cancer in Serbia over
the last decade and a comparison with European and
world figures. The main findings of this study are the
significant increase of overall cancer incidence and mor-
tality within the observed period in Serbia as well as the
alarmingly high mortality rates of Serbia compared to
the rest of Europe.
Per-site comparison of incidence and mortality with
respective European estimates identified four cancer
sites that should attract serious attention. In 2008, Serbia
was the country with the highest mortality due to breast
cancer in Europe, while incidence of cervical cancer was
only slightly lower than the highest European rate,
recorded in Romania. In the male population of Serbia,
incidence and mortality rates of lung and colorectal can-
cers, although not the highest in Europe, were well
above average estimates. Oppositely, the only rate within
the comparison found to be lower in Serbia was prostate
cancer incidence.The comparatively high levels of cancer incidence
observed can, to a large extent, be attributed to the
prevalence of cancer risk factors. For instance, tobacco
and alcohol consumption have a well-established associ-
ation with increased risk of several cancer types [18,19].
These health hazards are reported as excessively present
in contemporary Serbia, where half of all men and one
third of all women actively smoke [20], while 40% of the
total population consumes alcohol occasionally or on
everyday basis [21]. Moreover, risk factors for cancer
such as lack of physical activity and obesity [22,23] are
also largely present among the Serbian population. In
particular, in a representative sample of Serbian adults
only a 10% was found to be engaged to a daily physical
activity and about 55% were overweight [24]. Although
some action in controlling risk factors in the population
have been introduced by the Serbian health care system,
as for example the creation of a legislation framework
for tobacco control [20], more effort towards risk-factor
reductions is needed. Finally, the country is still in
an economic transition which influences the people’s
Figure 4 (A) Comparison of Serbian incidence ASR-Ws with the GLOBOCAN 2008 estimates –women; (B), Comparison of Serbian
mortality ASR-Ws with the GLOBOCAN 2008 estimates – women. N Europe – Northern Europe, S Europe – Southern Europe, W Europe –
Western Europe, CE Europe – Central Eastern Europe. B&H – Bosnia and Herzegovina. * - Eureopan country with the lowest incidence/mortality
ASR-W. ** - European country with the highest incidence/mortality ASR-W.
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trends in cancer epidemiology [25].
In addition to this high level of incidence in compari-
son to the rest of Europe, Serbia is confronted with an
even higher relative mortality rate. Since it is known that
cancer survival declines with the increase of mortality/
incidence ratio [26], cancer survival in Serbia might be
poorer than in other European countries/regions. Fur-
thermore, this could also be a sign of delayed cancer
diagnosis, which is the main differentiating factor for
survival in several cancer types [27]. Lack of screening
methods that can facilitate early cancer detection is one
of the reasons behind this high relative mortality. Par-
ticularly, the opportunistic screening methods available
usually do not target the general population, or at least
the population at risk. For example, planning of an orga-
nized, cytology-based screening for cervical cancer
started more than a decade ago [28], yet it still remains
on the level of an opportunistic program with high
coverage in younger and quite low coverage in elderly
women [29]. The implementation of screening programs
such as cytology-based screening or mammography
could facilitate early detection in cervical and breastcancer respectively and thereby positively impact sur-
vival [30,31]. Additionally, improvement in survival after
colorectal cancer would be possible through the applica-
tion of a fecal occult blood test [32]. Hence, prevention
and early diagnosis could improve survival and decrease
cancer mortality in Serbia.
The trend of incidence of breast cancer in Serbia
largely follows the increasing incidence pattern that is
currently observed in the rest of the European countries
[33]. One reason behind such increase in Serbia is the
recent implementation of opportunistic mammography
screening [34]. However, breast cancer mortality in Serbia
has so far remained constant in contrast to the decreas-
ing trend observed in breast cancer mortality through-
out Europe and especially in the northern and western
European countries [35]. Since the decrease of breast
cancer mortality in Europe has been mainly attributed
to advancements in therapy [35], it could be argued that
the absence of similar trend in Serbia is caused by
delays in the adoption of new treatment alternatives. In
men, although prostate cancer incidence in Serbia still
remains generally low compared to the rest of Europe,
the steep increase of the incidence might be attributed
Mihajlović et al. BMC Cancer 2013, 13:18 Page 10 of 11
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use of prostate specific antigen (PSA) testing [36].
Prior epidemiological studies that were conducted for
Serbia mainly focused on specific cancer sites. Most of
them pinpointed the increasing cancer incidence and
mortality [7-9,28,37]. More specifically, high cervical
cancer incidence relative to other European countries
was noted already at the beginning of the last decade
[28,37], the insufficiency of screening utilization was
identified as the main cause for this excess in incidence.
Increasing trends in breast and lung cancer in Vojvodina
were observed in the periods from 1987 until 2001 and
from 1996 until 2005, respectively [7,8]. Finally, one
study estimated the burden of several cancers in Serbia
relative to that in Europe for the year 2000 [9]. This
study relied on local data from both cancer registries of
Serbia and identified the considerably higher burden of
the disease in Serbia.
Our study is also confronted with a number of limita-
tions. A major limitation is the absence of nation-wide
cancer survival and prevalence data. Survival and preva-
lence estimates are typically included in nation-wide
cancer epidemiology studies, yet this information is not
available for Serbia. Such estimates would require fre-
quent follow up on patient cohorts, something that, due
to financial constraints, would be nearly impossible in
Serbia nowadays. Moreover, comparisons across Europe
were done only with the countries that had the highest
and lowest incidence and mortality rates, in order to
gain insight on the magnitude of a certain ASR-W in
Europe. Additionally, the lack of age-specific cancer in-
cidence and mortality estimates from GLOBOCAN
2008 did not permit a formal statistical comparison be-
tween the ASR-Ws of Serbia and the other European
regions and countries. In a more detailed analysis, pres-
entation of age-specific cancer evidence from a larger
number of European countries could give more pre-
cisely the relative position of Serbia with respect to its
cancer epidemiology.
Conclusion
Incidence and mortality of all cancer sites combined in
Serbia have shown a steady increase in the first decade
of their systematic reporting. Overall mortality rates in
both genders appear markedly high relative to European/
global estimates. Site-specific comparison revealed alar-
mingly high rates for four cancer locations: breast and cer-
vical cancer in women and lung and colorectal cancer in
men. In light of these findings, we believe that better con-
trol of known risk factors should lead to positive change
in Serbian cancer epidemiology. Furthermore, prevention
and early diagnosis, especially of breast and cervical can-
cers, seem to be the areas where significant improvements
still could be made.Competing interests
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